VistaGen Therapeutics, Inc. (VTGN) Ownership
VTGN ownership summary
as of October 18, 2026- Institutions
- 31.1% of shares outstanding
- Insiders
- 0.37% of shares outstanding
- Shares outstanding
- 44.4M
- Float
- 41.4M shares available to trade
- Short interest
- 8.48% 3.8M shares short
- Days to cover
- 0.13 short interest up 38.6% vs prior month
- Institutions 31.05%
- Insiders 0.37%
- Other investors 68.57%
VTGN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | COMMODORE CAPITAL LP | 6.28% | 2.8M | $557,724 | +2.8M (0.0%) | June 30, 2026 |
| 2 | Vanguard Capital Management, LLC | 3.55% | 1.6M | $314,840 | — | June 30, 2026 |
| 3 | Two Sigma Investments LLC | 1.91% | 848K | $169,598 | +378,373 (+80.6%) | June 30, 2026 |
| 4 | Acadian Asset Management LLC | 1.79% | 795K | $158,916 | +204,916 (+34.8%) | June 30, 2026 |
| 5 | Renaissance Technologies Corp | 1.65% | 730K | $146,100 | +439,200 (+150.8%) | June 30, 2026 |
| 6 | StemPoint Capital LP | 1.39% | 617K | $123,350 | −616,749 (−50.0%) | June 30, 2026 |
| 7 | Ikarian Capital, LLC | 1.17% | 519K | $103,815 | — | June 30, 2026 |
| 8 | AdvisorShares Investments, LLC | 0.99% | 439K | $87,729 | +161,533 (+58.3%) | June 30, 2026 |
| 9 | Luminus Management, LLC | 0.91% | 403K | $80,623 | +7,062 (+1.8%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 0.82% | 365K | $73,000 | −88,389 (−19.5%) | June 30, 2026 |
| 11 | ADAR1 Capital Management LLC | 0.79% | 351K | $70,228 | −400,000 (−53.3%) | June 30, 2026 |
| 12 | BlackRock Inc | 0.78% | 345K | $69,086 | −103,075 (−23.0%) | June 30, 2026 |
| 13 | Group One Trading, LLC | 0.69% | 304K | $60,877 | +284,510 (+1,431.5%) | June 30, 2026 |
| 14 | Verdad Advisers, LP | 0.66% | 293K | $58,669 | +108,405 (+58.6%) | June 30, 2026 |
| 15 | Vanguard Fiduciary Trust Co | 0.49% | 218K | $43,540 | — | June 30, 2026 |
| 16 | Jane Street Group LLC | 0.37% | 165K | $32,965 | −107,984 (−39.6%) | June 30, 2026 |
| 17 | BOOTHBAY FUND MANAGEMENT, LLC | 0.30% | 135K | $26,914 | — | June 30, 2026 |
| 18 | State Street Corp | 0.27% | 121K | $24,223 | — | June 30, 2026 |
| 19 | XTX Topco Ltd | 0.27% | 118K | $23,676 | −34,469 (−22.6%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.18% | 81K | $16,165 | +8,168 (+11.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 9 holders added 4.4M shares and 6 cut 1.4M.
VTGN top mutual fund and ETF holders
8 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.62% | 1.2M | $232,091 | — | August 31, 2026 |
| 2 | AdvisorShares Psychedelics ETF | 1.22% | 543K | $108,537 | — | September 30, 2026 |
| 3 | Fidelity Extended Market Index | 0.52% | 230K | $45,984 | +40,364 (+21.3%) | August 31, 2026 |
| 4 | Abante Quant Value FI | 0.44% | 196K | $39,120 | — | August 31, 2026 |
| 5 | Fidelity Series Total Market Index | 0.11% | 49K | $9,781 | — | August 31, 2026 |
| 6 | Fidelity Total Market Index | 0.11% | 47K | $9,392 | — | August 31, 2026 |
| 7 | Vanguard U.S. Eq Idx £ Acc | 0.02% | 11K | $2,162 | — | August 31, 2026 |
| 8 | Guggenheim Active Allocation Fund | <0.01% | 76 | $15 | +38 (+100.0%) | May 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
VTGN insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-08-07 | Commodore Capital Lp | Buy | $23.15 | 775,756 | $18.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
VTGN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns VTGN
Institutional investors own 31.1% of VistaGen Therapeutics's shares and insiders 0.37%. The largest holder is COMMODORE CAPITAL LP with 6.28% of the shares (2.8M), as of June 30, 2026. Among the top 20 institutions, 9 added shares and 6 reduced their stake in the latest filings. Short interest is 8.48% of the float, or 0.13 days of average trading volume. The share count rose 97,214.3% since 2014.
Related: VTGN analyst forecast, VTGN key metrics. See the VTGN stock overview for the latest quote and news.
VTGN ownership FAQ
Who owns the most VistaGen Therapeutics stock?
The largest shareholders of VistaGen Therapeutics are COMMODORE CAPITAL LP (6.28%), Vanguard Capital Management, LLC (3.55%), Two Sigma Investments LLC (1.91%), Acadian Asset Management LLC (1.79%), Renaissance Technologies Corp (1.65%).
What percentage of VistaGen Therapeutics is owned by institutions?
Institutions hold 31.1% of VistaGen Therapeutics's shares outstanding; insiders hold 0.37%.
Which funds own VistaGen Therapeutics?
The largest fund holders of VistaGen Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.62%), AdvisorShares Psychedelics ETF (1.22%), Fidelity Extended Market Index (0.52%), Abante Quant Value FI (0.44%), Fidelity Series Total Market Index (0.11%).
What is VistaGen Therapeutics's short interest?
3.8M shares of VistaGen Therapeutics were sold short, 8.48% of the float; at the average daily volume it would take 0.13 days to cover.
Are insiders buying or selling VistaGen Therapeutics?
Of the latest 1 reported insider transactions in VistaGen Therapeutics (since August 7, 2023), 1 were purchases and 0 were sales.
How many shares of VistaGen Therapeutics are outstanding?
VistaGen Therapeutics has 44.4M shares outstanding, of which 41.4M are in the public float.